Our group focused on synthesizing inorganic metal drugs for targeting cancer stem cells and I've been mainly working with cobalt(III) complexes anti-breast cancer stem cells. The cobalt(III) complexes were synthesized and fully characterized by NMR, MS, IR, elemental analysis and X-ray crystal structure. The pure cobalt(III) complexes would be monitored stability via UV-vis, MS or NMR then further tested toxicity and mechanism of cell death in vitro using biological techniques including MTT assay, microscope, flow cytometry and western blot. Promising complexes would be continued for in vivo study.
We developed a catalyst containing different ratios of bismuth(Bi) and cerium(Ce) for catalysing nitrogen reduction.
[2] J. Fang, P. Gerschel, K. Singh, U.-P. Apfel and K. Suntharalingam, Cobalt(III)–Macrocyclic Scaffolds with Anti-Cancer Stem Cell Activity. Molecules. 2024, 29, 2743.
[3] J. Fang, K. Singh and K. Suntharalingam, Anti-Cancer Stem Cell Cobalt(III)-Polypyridyl Complexes Containing Salicylic Acid. Inorganics. 2024, 12, 202.
[4] J. Fang*, Y. Li*, K. Singh, F. Ortu and K. Suntharalingam, An Immunogenic Anti-Cancer Stem Cell Bi-nuclear Copper(ii)-Flufenamic Acid Complex. Dalton Transactions, 2024, 53, 6410-6415. (*: equal contribution)
[5] P. B. Osei, J. Northcote-Smith, J. Fang, K. Singh, F. Ortu and K. Suntharalingam, The Bulk Breast Cancer Cell and Breast Cancer Stem Cell Activity of Binuclear Copper(II)-Phenanthroline Complexes. Chemistry – A European Journal, 2023, 29, e202301188.